A machine-learning approach based on 409 treatments to predict optimal number of iodine-125 seeds in low-dose-rate prostate brachytherapy

Nicolas Boussion, PhD1,2, Ulrike Schick, MD, PhD1,2, Gurvan Dissaux, MD2, Luc Ollivier, MD2, Gaëlle Goasduff, MSc2, Olivier Pradier, MD, PhD1,2, Antoine Valeri, MD, MD1,2, Dimitris Visvikis, PhD1
1LaTIM, INSERM, UMR 1101, Univ Brest, Brest, France, 2Radiation Oncology Department, CHU, Brest, France

Abstract

Purpose: Low-dose-rate brachytherapy is a key treatment for low-risk or favorable intermediate-risk prostate cancer. The number of radioactive seeds inserted during the procedure depends on prostate volume, and is not easy to predict without pre-planning. Consequently, a large number of unused seeds may be left after treatment. The objective of the present study was to predict the exact number of seeds for future patients using machine learning and a database of 409 treatments.

Material and methods: Database consisted of 18 dosimetric and efficiency parameters for each of 409 cases. Nine predictive algorithms, based on machine-learning were compared in this database, which was divided into training group (80%) and test group (20%). Ten-fold cross-validation was applied to obtain robust statistics. The best algorithm was then used to build an abacus able to predict number of implanted seeds from expected prostate volume only.

As an evaluation, the abacus was also applied on an independent series of 38 consecutive patients.

Results: The best coefficients of determination $R^2$ were given by support vector regression, with values attaining 0.928, 0.948, and 0.968 for training set, test set, and whole set, respectively. In terms of predicted seeds in test group, mean square error, median absolute error, mean absolute error, and maximum error were 2.55, 0.92, 1.21, and 7.29, respectively. The use of obtained abacus in 38 additional patients resulted in saving of 493 seeds (393 vs. 886 remaining seeds).

Conclusions: Machine-learning-based abacus proposed in this study aims at estimating the necessary number of seeds for future patients according to past experience. This new abacus, based on 409 treatments and successfully tested in 38 new patients, is a good alternative to non-specific recommendations.

Key words: low-dose-rate brachytherapy, prostate cancer, radioactive seeds, machine-learning.

Purpose

Low-dose-rate brachytherapy (LDR-BT) is a treatment recommended for patients suffering from low-risk or favorable intermediate-risk prostate cancer [1-3]. For this purpose, specific radioactive seeds (typically, iodine-125 [$^{125}$I] or palladium-103 [$^{103}$Pd]) are inserted permanently inside the prostate using dedicated transperineal needles, which are manually or semi-automatically introduced [4, 5]. LDR-BT can be performed without any pre-planning, but the number of seeds to be implanted depends on prostate volume. Providers of technical devices often recommend ordering a satisfactory number of seeds for patient, according to expected prostate volume. It is then reasonable to add a volume margin (for example 10%) or to add supplementary seeds (e.g., 10) in order to have sufficient number of seeds for treatment. As a consequence, the amount of unused seeds after treatment can vary widely. Since the volume of prostate as measured during treatment may differ from the expected one, there may remain a high number of unused radioactive seeds, which need to be stored and managed according to legal and strict radiation protection procedures. These remaining seeds are usually stored for natural decay and later returned to manufacturer. For a center treating 100 patients a year, a mean of 20 unused seeds per patient would lead to an annual amount of 2,000 unexploited radioactive seeds. This is both costly and time-consuming, not to mention the environmental impact of such an amount of unused radioactive sources. In this context, the aim of the present
study was to propose a tool able to predict the exact number of seeds required for a given patient. As stated above, general recommendations are sometimes provided by manufacturers; however, it quickly becomes clear to develop prediction methods, specific for each institutions’ prostate LDR-BT technique and its constraints [6]. In the past, studies have been conducted in an attempt to build practical tools, from curve fitting [7, 8] to nomograms [9]. However, these interesting methods are somewhat out-of-date [10, 11], and may no longer correspond to today’s medical devices or practical habits. Others approaches are specific to certain dose prescriptions, e.g., 125 Gy [12], or restricted to certain radionuclides, such as 103 Pd [13].

For this reason, the method proposed here was based on machine-learning applied to an existing database to build an abacus able to predict the exact number of necessary seeds for future patients.

There were several objectives of the study. First, dosimetric and efficiency data from 409 successive treatments were presented. This database was then used in a systematic machine-learning approach to find an algorithm with satisfactory predictive capability. Finally, this algorithm was chosen to generate an abacus representing past experience and capable of predicting the number of seeds for future patients, which was based solely on the expected prostate volume and estimated before treatment. The abacus was also assessed in an independent series of 38 new patients.

Material and methods

Technical platform and LDR-BT database

Database consisted of a set of 409 treatments performed by a dedicated LDR-BT team in our hospital between January 2015 and November 2020. Each patient had a series of 125I radioactive titanium-coated seeds inserted in his prostate, using a conventional implantation pattern, with approximately 75% of the seeds at peripheral part of the prostate and 25% deeper inside the organ. Treatments were planned intra-operatively only, with no pre-planning. Technical solution was supported with BARD Medical Division, using B-mode endorectal echography (BK Medical) and VariSeed v. 9.0 treatment planning system (Varian Medical Systems). Endorectal probe was monitored using a dedicated stepper (Civco EX3). Prescription dose was set at 160 Gy to the prostate, with specific dosimetric constraints for both urethra and rectum as organs-at-risk.

Considering seed strength, there were two main strategies, one advocating the same activity for all patients, the other adapting activity to the expected prostate volume. We have chosen the latter approach with the following activities: 0.398 mCi for \( V_p < 25 \text{ cm}^3 \), 0.460 mCi for \( V_p < 40 \text{ cm}^3 \), 0.498 mCi for \( V_p < 50 \text{ cm}^3 \), 0.543 mCi for \( V_p < 60 \text{ cm}^3 \), and 0.585 mCi for \( V_p = 60 \text{ cm}^3 \) (1 mCi = 1.27 U = 1.27 cGy cm²/h for 125I). Prostates with a volume less than 25 cm³ are generally considered very small, and dosimetric planning becomes more challenging in such cases, especially with regard to the risk of hot spots for urethra and rectum. For this reason, seed strength is significantly reduced when \( V_p < 25 \text{ cm}^3 \), in order to facilitate planning. To conclude, it is important to note that seed strength should be fixed in advance as a function of \( V_p \).

A list of 25 dosimetric and efficiency parameters was carefully reported at the end of each treatment. For the prostate, parameters, including expected or pre-implant volume, volume measured during treatment, \( D_{90\%}, V_{200\%}, V_{100\%}, V_{90\%} \), and \( V_{60\%} \) were assessed. Concerning organs-at-risk, \( D_{10\%} \) and \( D_{90\%} \) were evaluated for the urethra, while \( D_{2cm^3}, D_{0.1cm^3} \) and \( V_{100\%} \) were assessed for the rectum. The expected prostate volume was a pre-implant rough estimate obtained from an ellipsoid that was manually drawn on echography during biopsy procedure [15, 16]. This volume estimation was made a few weeks before the actual treatment day. Volume measured during treatment was obtained by means of a meticulous manual delineation on 1 mm transverse B-mode ultrasound slices. Measurement of this volume on the day of treatment was performed in two steps. First contouring was performed before the insertion of needles in order to exploit good quality of ultrasound images, without metallic artefacts. This contouring was then adjusted after insertion of the needles to account for any deformation of the prostate caused by oedema.

From now onwards, the expected or pre-implant prostate volume would be referred to as ‘\( V_p^{\text{pre}} \)’, while the prostate volume measured during treatment would be referred to as ‘\( V_p \)’. The number of inserted needles (both peripheral and internal) and the number of implanted seeds (both peripheral and internal) as well as the amount of radioactivity, total, peripheral, internal, and per seed, with quantities of ordered and delivered seeds were all documented.

Data selection for machine-learning training

Data features used to train machine-learning algorithms for regression purposes significantly influence performance that can be achieved. Irrelevant or partially relevant characteristics can negatively impact model performance. Additionally, it is important to reduce data redundancy to limit overfitting and to improve accuracy. In this context, not all data were used in the current study. More specifically, linearly dependent parameters or those clearly uncorrelated to the number of seeds or, on the contrary, perfectly related to the number of seeds, were removed from the treatment database.

Two classical data preparation methods were also tested to possibly improve performance of prediction. The first method was standardization during which, features values were transformed to a Gaussian distribution, with a mean of zero and a standard deviation of 1. The second method was scaling, where features values were re-scaled into the range of 0-1.

Machine-learning assessment

The objective was to find an algorithm able to correctly predict the number of implanted seeds. However, it is impossible to predict in advance an algorithm that is best suited to a given database. For this reason, a systematic
approach was used, in which classical machine-learning algorithms, well-adapted to regression, were analyzed and compared. Non-linear algorithms were support vector machines for regression (SVR) [17], K nearest neighbors regressor (KNN) [18], multilayer perceptron (MLP) [19], and classification and regression trees (CART) [20]. Linear algorithms included ElasticNet (EN) [21], Lasso regression [22], and Ridge regression [23]. Also, CatBoost [24] and XGBoost [25] classical gradient boosting approaches were tested.

The key to a correct comparison of machine-learning algorithms is to ensure that each algorithm is trained in the same way and on the same data. In this context, ten-fold cross-validation was used to obtain reliable statistics during training process. Eighty percent of the whole dataset (i.e., 327 treatments) were used for this purpose, while the remaining 20% were used for testing a trained model on an independent set of treatments. Comparison of predictions was quantified with coefficient of determination $R^2$, with best possible score of 1. Training and testing of algorithms were performed using Python v. 3.7.6, scikit-learn v. 0.22.2 open-source toolkit [26], and Keras v. 2.3.1 for MLP implementation.

**Abacus for future patients**

An algorithm that obtained the best $R^2$ score in predicting the number of seeds from the dataset was used to build a practical abacus. From clinical point of view, the only parameter available prior to treatment was the pre-implant prostate volume $V_p$, whereas the analyzed algorithms were trained and tested on a wide series of data obtained principally at the end of treatment. As a consequence, such a trained algorithm could not be used directly for upcoming patients. Therefore, the clinical dataset (i.e., 327 treatments) was used for this purpose, while the remaining 20% were used for testing a trained model on an independent set of treatments. Comparison of predictions was quantified with coefficient of determination $R^2$, with best possible score of 1. Training and testing of algorithms were performed using Python v. 3.7.6, scikit-learn v. 0.22.2 open-source toolkit [26], and Keras v. 2.3.1 for MLP implementation.

**Results**

Table 1 summarizes the 25 dosimetric and efficiency features analyzed from 409 treatments of the database. Figure 1 provides an overview of the real number of implanted seeds, with respect to the pre-implant volume $V_p$ and $V_r$ prostate volume measured during treatment $V_r$. Mean values for $V_p$ and $V_r$ were $41.8 \pm 10.0 \text{ cm}^3$ (min = 20, max = 65) and $42.6 \pm 11.3 \text{ cm}^3$ (min = 18.0, max = 71.6), respectively, while the mean number of implanted seeds was 64.2 $\pm 9.0$. In sixty-seven patients, the number of remaining seeds was equal or more than 20, with a maximum of 37 remaining seeds. Circles at regular intervals, such as 25 cm$^3$, 30 cm$^3$, and so on, were more frequent, because values were very often rounded by the operating physician.

Concerning the machine-learning analysis, only 18 features out of initial 25 were used to reduce redundancy and overfitting. It was indeed ineffective to consider the total number of needles $N_t$ when internal $N_i$ and peripheral $N_p$ needles were already known. Total, peripheral, and internal activities in mCi were also discarded due to direct correlation with the numbers of implanted seeds. The 18 features used are presented in Table 1, which are underlined. Coefficient of determination $R^2$ using 10-fold cross validation on the trained dataset is described in Figure 2 for each tested algorithm. The best result was obtained by using SVR algorithm on standardized data, with a $0.928 \pm 0.023 R^2$. Once trained, this SVR model was applied to an independent test in dataset and the value of obtained $R^2$ was 0.948, while mean square error, median absolute error, mean absolute error, and maximum error were 5.58, 1.31, 1.78, and 7.14, respectively. When the trained SVR model was applied to the whole set of 409 treatments, these values became 2.55, 0.92, 1.21, and 7.29, respectively. When the trained SVR model was applied to the whole set of 409 treatments, these values became 2.55, 0.92, 1.21, and 7.29, respectively. When the trained SVR model was applied to the whole set of 409 treatments, these values became 2.55, 0.92, 1.21, and 7.29, respectively. When the trained SVR model was applied to the whole set of 409 treatments, these values became 2.55, 0.92, 1.21, and 7.29, respectively. When the trained SVR model was applied to the whole set of 409 treatments, these values became 2.55, 0.92, 1.21, and 7.29, respectively. When the trained SVR model was applied to the whole set of 409 treatments, these values became 2.55, 0.92, 1.21, and 7.29, respectively.
It is important to note that a 10% margin was added in both cases to limit the probability of running out of seeds.

Discussion

Low-dose-rate brachytherapy remains a key treatment for the prostate, and still benefits from both technological innovations [27-30] and clinical research [31-33]. The number of seeds implanted in the prostate during a procedure mostly depends on the volume of prostatic gland. This latter can be estimated before treatment in order to predict a sufficient number of seeds, but the precise delineation performed during treatment may lead to a different measured volume (Figure 5). There are many reasons for this. First, pre-treatment volume is estimated using approximated methods, most of the time based on three axes, which define an ellipsoid theoretically similar to the shape of the prostate. Second, in the day of actual treatment, the volume is measured by careful delineation of the prostate slice by slice using endorectal echography. Another reason is an inflammation that sometimes occurs after insertion of needles, with an increase in prostate volume due to oedema [34]. As a consequence, the expected (pre-implant) and actual (during treatment) volumes differ. Providers of medical devices propose general methods for ordering the seeds that are necessary for a correct dosimetric coverage of the prostate. However, these methods are recommendations that cannot be specific to all habits and objectives of every team performing brachytherapy. Each center has its own procedure and material for estimating the volume before treatment. In the same way, experience may influence brachytherapy

| Feature  | Mean | Median | SD  | Min | Max | Description                                           |
|----------|------|--------|-----|-----|-----|-------------------------------------------------------|
| $V_{pi}$ | 42   | 40     | 10  | 20  | 65  | Pre-implant prostate volume (cm³)                     |
| $V_t$    | 43   | 43     | 11  | 18  | 72  | Prostate volume measured during treatment (cm³)       |
| Nt       | 20   | 20     | 3   | 13  | 29  | Total number of needles                               |
| Np       | 14   | 14     | 2   | 8   | 19  | Number of peripheral needles                         |
| Ni       | 6    | 6      | 2   | 3   | 12  | Number of internal needles                            |
| St       | 64   | 65     | 9   | 39  | 86  | Total number of implanted seeds                       |
| Sp       | 46   | 46     | 7   | 25  | 72  | Number of peripheral seeds                            |
| Si       | 18   | 18     | 5   | 8   | 36  | Number of internal seeds                              |
| As       | 0.510| 0.500  | 0.040| 0.374| 0.609| Activity per seed (mCi)                               |
| At       | 32.9 | 33.2   | 6.3 | 18.3| 48.2| Total activity (mCi)                                  |
| Ap       | 23.6 | 23.4   | 4.8 | 11.9| 38.5| Peripheral activity (mCi)                             |
| Ai       | 9.3  | 9.3    | 2.8 | 3.6 | 20.1| Internal activity (mCi)                               |
| As_th    | 0.498| 0.500  | 0.040| 0.398| 0.585| Activity per seed in mCi (theoretical, according to manufacturer’s recommendations) |
| Ns_th    | 77   | 78     | 8   | 57  | 92  | Total number of seeds (theoretical, according to manufacturer’s recommendations) |
| $D_{90\%}$ | 179.8| 179.9 | 4.9 | 160.4| 190.7| Dose received by 90% of prostate volume (Gy)         |
| $V_{90\%}$ | 9.7  | 9.3    | 2.8 | 3.6 | 21.1| Prostate volume receiving 90% of prescribed dose (cm³) |
| $V_{200\%}$ | 21.5 | 20.9   | 5.9 | 9.1 | 40.0| Prostate volume receiving 200% of prescribed dose (cm³) |
| $V_{150\%}$ | 41.3 | 41.3   | 11.1| 17.2| 68.3| Prostate volume receiving 150% of prescribed dose (cm³) |
| $V_{100\%}$ | 42.2 | 42.1   | 11.2| 17.8| 70.1| Prostate volume receiving 100% of prescribed dose (cm³) |
| $D_{10\%}$ | 187.3| 186.6 | 6.4 | 165.6| 210.0| Dose received by 10% of urethra volume (Gy)          |
| $D_{30\%}$ | 180.0| 180.0 | 6.2 | 140.4| 197.0| Dose received by 30% of urethra volume (Gy)          |
| $D_{max}$ | 110.1| 111.7 | 12.0| 63.9 | 146.8| Max dose received by 2 cm³ of rectum volume (Gy)     |
| $D_{0.1cm^3}$ | 150.5| 150.9 | 11.9| 96.4 | 193.5| Max dose received by 0.1 cm³ of urethra volume (Gy)   |
| $V_{100\%}$ | 0.05 | 0.03  | 0.07| 0.00 | 0.36| Rectum volume receiving 100% of prescribed dose (cm³) |
| Sdel     | 81   | 80     | 10  | 59  | 104 | Number of seeds delivered by manufacturer             |
team to adopt new choices of dosimetric objectives and doses to organs-at-risks, which can lead to more or less number of inserted seeds for a given prostate volume. As the number of patients increases, manufacturer’s recommendations may become unsuitable to local practice. For these reasons, the number of remaining seeds per patient may become very high. This poses a problem in terms of material management, cost-effectiveness, and working time, not to mention an environmental impact of unnecessarily produced radioactive sources. In this context, it seems logical to imply a method capable of calculating the number of seeds for future cases according to already treated patients, giving the habits of team involved.

This was the objective of the current study, in which machine-learning algorithms were applied to a series of 409 consecutive treatments. A simpler solution could have been to choose a mean or median $St$ value for each typical $V_{pi}$ volume, but the observed numbers of implanted seeds appeared to be complicated and intricated distributions, with significant overlaps between the volumes (Figure 4). Therefore, it seemed reasonable to make the most of all relevant data available, a choice of well-adapted machine-learning technique. The obtained results show that the mean difference between the manufacturer’s recommendation and the proposed abacus was 15.9 seeds (min = 3, max = 24).

When using machine-learning algorithms, it is almost impossible to predict most suitable model for studied dataset. For this reason and to evaluate a series of classical models, cross-validation-based re-sampling method was applied in order to obtain an estimate of accuracy of each model on unseen data. Tested algorithms were the representative of usual approaches with both linear and non-linear dependencies. For this reason, some of them are traditional linear modeling methods, including Ridge Regression, Elastic Net, Lasso, as well as non-linear models like Decision Trees (CART), K-Nearest Neighbors (KNN), Random Forest (RF), Support Vector Regression (SVR), Extreme Gradient Boosting (XGB), and CatBoost. After cross-validation process, RF and XGB showed the best performance in terms of both accuracy and time to calculate predictions, whereas SVR and CatBoost showed the worst results. It seems that multivariate models with large number of parameters, like SVR and CatBoost, are not well adapted to the size of the current study. Depending on the number of features and size of the data, models were scaled using MaxAbsScaler method and standardized using MinMaxScaler method. This allowed to use the same methodology for all studies with different numbers of features and data size. In the case of large number of features, such as in the current study, applying scaling methods is strongly recommended. The best results in terms of accuracy were obtained with the use of SVR with standardized features, XGB with standardized features, and CatBoost with raw data. Cross-validation accuracy was obtained in a range of $R^2$ from 0.5 to 0.75. The obtained results show that the mean difference between the manufacturer’s recommendation and the proposed abacus was 15.9 seeds (min = 3, max = 24).

When using machine-learning algorithms, it is almost impossible to predict most suitable model for studied dataset. For this reason and to evaluate a series of classical models, cross-validation-based re-sampling method was applied in order to obtain an estimate of accuracy of each model on unseen data. Tested algorithms were the representative of usual approaches with both linear and non-linear dependencies. For this reason, some of them are traditional linear modeling methods, including Ridge Regression, Elastic Net, Lasso, as well as non-linear models like Decision Trees (CART), K-Nearest Neighbors (KNN), Random Forest (RF), Support Vector Regression (SVR), Extreme Gradient Boosting (XGB), and CatBoost. After cross-validation process, RF and XGB showed the best performance in terms of both accuracy and time to calculate predictions, whereas SVR and CatBoost showed the worst results. It seems that multivariate models with large number of parameters, like SVR and CatBoost, are not well adapted to the size of the current study. Depending on the number of features and size of the data, models were scaled using MaxAbsScaler method and standardized using MinMaxScaler method. This allowed to use the same methodology for all studies with different numbers of features and data size. In the case of large number of features, such as in the current study, applying scaling methods is strongly recommended. The best results in terms of accuracy were obtained with the use of SVR with standardized features, XGB with standardized features, and CatBoost with raw data. Cross-validation accuracy was obtained in a range of $R^2$ from 0.5 to 0.75. The obtained results show that the mean difference between the manufacturer’s recommendation and the proposed abacus was 15.9 seeds (min = 3, max = 24).

When using machine-learning algorithms, it is almost impossible to predict most suitable model for studied dataset. For this reason and to evaluate a series of classical models, cross-validation-based re-sampling method was applied in order to obtain an estimate of accuracy of each model on unseen data. Tested algorithms were the representative of usual approaches with both linear and non-linear dependencies. For this reason, some of them are traditional linear modeling methods, including Ridge Regression, Elastic Net, Lasso, as well as non-linear models like Decision Trees (CART), K-Nearest Neighbors (KNN), Random Forest (RF), Support Vector Regression (SVR), Extreme Gradient Boosting (XGB), and CatBoost. After cross-validation process, RF and XGB showed the best performance in terms of both accuracy and time to calculate predictions, whereas SVR and CatBoost showed the worst results. It seems that multivariate models with large number of parameters, like SVR and CatBoost, are not well adapted to the size of the current study. Depending on the number of features and size of the data, models were scaled using MaxAbsScaler method and standardized using MinMaxScaler method. This allowed to use the same methodology for all studies with different numbers of features and data size. In the case of large number of features, such as in the current study, applying scaling methods is strongly recommended. The best results in terms of accuracy were obtained with the use of SVR with standardized features, XGB with standardized features, and CatBoost with raw data. Cross-validation accuracy was obtained in a range of $R^2$ from 0.5 to 0.75. The obtained results show that the mean difference between the manufacturer’s recommendation and the proposed abacus was 15.9 seeds (min = 3, max = 24).

When using machine-learning algorithms, it is almost impossible to predict most suitable model for studied dataset. For this reason and to evaluate a series of classical models, cross-validation-based re-sampling method was applied in order to obtain an estimate of accuracy of each model on unseen data. Tested algorithms were the representative of usual approaches with both linear and non-linear dependencies. For this reason, some of them are traditional linear modeling methods, including Ridge Regression, Elastic Net, Lasso, as well as non-linear models like Decision Trees (CART), K-Nearest Neighbors (KNN), Random Forest (RF), Support Vector Regression (SVR), Extreme Gradient Boosting (XGB), and CatBoost. After cross-validation process, RF and XGB showed the best performance in terms of both accuracy and time to calculate predictions, whereas SVR and CatBoost showed the worst results. It seems that multivariate models with large number of parameters, like SVR and CatBoost, are not well adapted to the size of the current study. Depending on the number of features and size of the data, models were scaled using MaxAbsScaler method and standardized using MinMaxScaler method. This allowed to use the same methodology for all studies with different numbers of features and data size. In the case of large number of features, such as in the current study, applying scaling methods is strongly recommended. The best results in terms of accuracy were obtained with the use of SVR with standardized features, XGB with standardized features, and CatBoost with raw data. Cross-validation accuracy was obtained in a range of $R^2$ from 0.5 to 0.75. The obtained results show that the mean difference between the manufacturer’s recommendation and the proposed abacus was 15.9 seeds (min = 3, max = 24).
Table 2. Predictive number of seeds according to pre-treatment prostate volume estimates. These values are now routinely used for our new patients. Seed strength is given in U (cGy cm\(^2\)/h), with 1 U = 0.787 mCi for 125I.

| Pre-implant prostate volume (cm\(^3\)) | Suggested seed activity (U) | Expected number of seeds |
|----------------------------------------|-----------------------------|--------------------------|
| 20                                     | 0.506                       | 53                       |
| 25                                     | 0.584                       | 53                       |
| 30                                     | 0.584                       | 55                       |
| 35                                     | 0.584                       | 60                       |
| 40                                     | 0.633                       | 61                       |
| 45                                     | 0.633                       | 68                       |
| 50                                     | 0.690                       | 68                       |
| 55                                     | 0.690                       | 69                       |
| 60                                     | 0.743                       | 74                       |

Fig. 3. Abacus obtained from trained SVR algorithm applied to artificial dataset. A) This abacus (plain line) is specific to our center and considers the 409 treatments. The number of seeds that is predicted according to the pre-treatment prostate volume is always lower than the result obtained with suggestions of manufacturer. Also, there is a noticeable difference when comparing with mean number of seeds. In particular, SVR model tends to predict more seeds than the mean value for \(V_{pi} < 40\) cm\(^3\), and less seeds than the mean value for \(V_{pi} > 40\) cm\(^3\). B) Corresponding total implanted activity according to the abacus (grey disks) and from experimental mean values (black squares). Polynomial fitting is also indicated.

Fig. 4. Abacus vs. manufacturer’s method: a comparison using data of 38 new patients. After treatment, the number of remaining seeds was 10 ±4 using the abacus, and 23 ±4 using the approach proposed by manufacturer.

Conclusions

In LDR-BT without pre-planning, the prostate volume is estimated before treatment for calculating the
required number of seeds. Prostate volume is also measured during treatment using careful manual contouring on trans-rectal ultrasound images. These two obtained values may significantly differ, due to, for example, oedema caused by implanted needles. While it is reasonable to add a safety margin to avoid running out of seeds on the day of treatment, it is important to start with the most accurate estimate possible. The reason is to generate a limited inventory of unused radioactive seeds, which are difficult to manage afterwards. In this context, the machine-learning-based abacus proposed in the present study could help in estimating the exact number of seeds for future patients, since it is based on a solid experience of 409 treatments.

Disclosure

The authors report no conflict of interest.

References

1. Pons-Llanasa O, Burgos-Burgos J, Roldan-Ortega S et al. Salvage I-125 brachytherapy for locally-recurrent prostate cancer after radiotherapy. Rep Pract Oncol Radiother 2020; 25: 754-759.
2. Levin-Epstein R, Cook RC, Wong JK et al. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. Radiother Oncol 2020; 151: 26-32.
3. Martell K, Roy S, Meyer T et al. Analysis of outcomes after non-contour-based dose painting of dominant intra-epithelial lesion in intra-operative low-dose rate brachytherapy. Helios 2020; 6: e04092.
4. Thomas L, Chemin A, Leduc N et al. Manual vs. automated implantation of seeds in prostate brachytherapy: Oncologic results from a single-center study. Brachytherapy 2018; 17: 214-220.
5. Inada M, Yokokawa M, Minami T et al. Dosimetry advantages of intraoperatively built custom-linked seeds compared with loose seeds in permanent prostate brachytherapy. J Contemp Brachytherapy 2017; 9: 410-417.
6. Lafata KJ, Bushe H, Aronowitz JN. A simple technique for the generation of institution-specific nomograms for permanent prostate cancer brachytherapy. J Contemp Brachytherapy 2014; 6: 293-296.
7. Aronowitz JN, Michalski JM, Merrick GS et al. Optimal equations for describing the relationship between prostate volume, number of sources, and total activity in permanent prostate brachytherapy. Am J Clin Oncol 2010; 33: 164-167.
8. Pouliot J, Tremblay D, Roy J et al. Optimization of permanent 125I prostate implants using fast simulated annealing. Int J Radiat Oncol Biol Phys 1996; 36: 711-720.
9. Cohen GN, Amols H, Zelefsky MJ et al. The Anderson nomograms for permanent interstitial prostate implants: a briefing for practitioners. Int J Radiat Oncol Biol Phys 2002; 53: 504-511.
10. DeSouza WD, Lee HK, Palmer MB et al. Is intraoperative nomogram-based overplanning of prostate implants necessary? Int J Radiat Oncol Biol Phys 2003; 56: 462-467.
11. Al-Qaisieh B, Brearley E, St Clair S et al. A study of a pre-treatment method to predict the number of 1-125 seeds required for prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006; 65: 304-307.
12. Taylor PK, Riegel AC. Reducing seed waste and increasing value of dynamic intraoperative implantation of Pd-103 seeds in prostate brachytherapy. J Appl Clin Med Phys 2018; 19: 383-388.
13. Zheng JJ, Stevens RN. Prostate implant nomograms for the North American Scientific 103Pd seed. Med Dosim 2003; 28: 185-188.
14. Elliott SL, Beaufort CL, Millar JL. Practical considerations in the selection of seed strength for prostate implants. J Appl Clin Med Phys 2015; 16: 53-61.
15. Fogh S, Doyle L, Yu A et al. A comparison of preplan transrectal ultrasound with preplan-CT in assessing volume and number of seeds needed for real-time ultrasound-based intra-operative planning in prostate 125I seed implantation. Brachytherapy 2010; 9: 335-340.
16. Marin L, Ezzi e M, Comperat E et al. Comparison of semi-automated and manual methods to measure the volume of prostate cancer on magnetic resonance imaging. Diagn Interv Imaging 2017; 98: 423-428.
17. Smola AJ, Schölkopf B. A tutorial on support vector regression. Statistics and Computing 2004; 14: 199-222.
18. Altman NS. An introduction to kernel and nearest neighbor non parametric regression. Am Stat 1990; 46: 175-185.
19. Hinton G. Connectionist learning procedures. Artificial Intelligence 1989; 40: 185-234.
20. Breiman L, Friedman J, Stone CJ et al. Classification and regression trees. 1st ed. Chapman and Hall/CRC, Boca Raton 1984.
21. Zou H, Hastie T. Regularization and variable selection via the elastic net. J R Stat Soc Series B Stat Methodol 2005; 67: 301-320.
22. Tibshirani R. Regression shrinkage and selection via the lasso: a retrospective. J R Stat Soc Series B Stat Methodol 2011; 73: 273-282.
23. Hoefl A. Application of ridge analysis to regression problems. Chem Eng Prog 1962; 58: 54-59.
24. Dorogush AV, Ershov V, Gulin A. CatBoost: gradient boosting with categorical features support. arXiv preprint arXiv: 1810.11363, 2018.
25. Chen T, Guestrin C. XGBoost: a scalable tree boosting system. Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, 2016 Aug 13-17; San Francisco, USA.
26. Pedregosa F, Varoquaux G, Gramfort A et al. Scikit-learn: machine learning in python. J Mach Learn Res 2011; 12: 2825-2830.
27. Dehghan E, Bharat S, Kung C et al. EM-enhanced US-based seed detection for prostate brachytherapy. Med Phys 2018; 45: 2357-2368.
28. Haworth A, Williams S. Focal therapy for prostate cancer: the technical challenges. J Contemp Brachytherapy 2017; 9: 383-389.
29. Rossa C, Usmani N, Sloboda R, Tavakoli M. A hand-held assistant for semiautomated percutaneous needle steering. IEEE Trans Biomed Eng 2017; 64: 637-648.
30. Lemaréchal Y, Bert J, Falconnet C et al. GGEMS-Brachy: GPU GEant4-based Monte Carlo simulation for brachytherapy applications. Phys Med Biol 2015; 60: 4987-5006.
31. Brun T, Bachaud JM, Graff-Cailleaud P et al. New approach of ultra-focal brachytherapy for low- and intermediate-risk prostate cancer with custom-linked I-125 seeds: A feasibility study of optimal dose coverage. Brachytherapy 2018; 17: 544-555.
32. Laing R, Uribe J, Uribe-Lewis S et al. Low-dose-rate brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse. BJU Int 2018; 122: 610-617.
33. Coquet JB, Delage F, Fourcade A et al. Evaluation of the “Quadrella” at 3 years: New index to assess functional and oncological performance specific to prostate brachytherapy. Brachytherapy 2018; 17: 782-787.
34. Chira C, Delouya G, Larrivée S et al. Prostate volume changes during permanent seed brachytherapy: an analysis of intra-operative variations, predictive factors and clinical implication. Radiat Oncol 2013; 8: 177-183.